Gastric cancer case study
inPROBE accurately detected the presence of the HER2 biomarker in peritoneal lavage samples in gastric cancer
Conclusions
Assessing HER2 expression in peritoneal lavage of gastric cancer patients is feasible and may improve the identification of eligible patients for targeted therapy
inPROBE technology presents an opportunity for HER2 determination in vitro during diagnostic laparoscopy in gastric cancer patients
HER2 is an established predictive and prognostic biomarker in gastric cancer patients, assessed by immunohistochemistry (IHC) in tumor cells
